Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2023

04 Jul 2023 11:00:00 By Nasdaq GlobeNewswire

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

30 Jun 2023 00:00:00 By Nasdaq GlobeNewswire

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

28 Jun 2023 19:00:54 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2023

27 Jun 2023 11:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2023

20 Jun 2023 11:00:00 By Nasdaq GlobeNewswire

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

14 Jun 2023 13:21:17 By Nasdaq GlobeNewswire

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome

13 Jun 2023 12:10:54 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2023

13 Jun 2023 11:00:00 By Nasdaq GlobeNewswire

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023

12 Jun 2023 00:00:00 By Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

09 Jun 2023 11:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023

06 Jun 2023 11:00:00 By Nasdaq GlobeNewswire

Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan

01 Jun 2023 00:00:00 By Nasdaq GlobeNewswire

Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023

31 May 2023 11:04:12 By Nasdaq GlobeNewswire

Ipsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023

31 May 2023 00:00:00 By Nasdaq GlobeNewswire

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

26 May 2023 07:20:29 By Nasdaq GlobeNewswire

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

17 May 2023 00:00:00 By Nasdaq GlobeNewswire

Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023

10 May 2023 11:00:00 By Nasdaq GlobeNewswire

Ipsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting

10 May 2023 07:00:00 By Nasdaq GlobeNewswire

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

27 Apr 2023 00:00:00 By Nasdaq GlobeNewswire

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

24 Apr 2023 01:00:00 By Nasdaq GlobeNewswire